Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 1 天前评分70
正文 · 原文
postMONARCH:
Abemaciclib After CDK4/6 Inhibitor Progression — PFS Benefit Without a Statistically Significant OS Improvement
@OncoAlert #BreastCancer #bcsm #ESMO26
54 浏览 · 6 赞 · 1 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Aya Mohamed | MSc, MD 🎗 · x.com